Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2014-08-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aims: To compare patient acceptance and procedural complication rates of the RAVI-Guide with those of the conventional lid speculum and caliper approach
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
NCT02144662
Lucentis KAV Study
NCT01570608
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
NCT01256632
Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy
NCT00516464
Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
NCT00942864
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients unable to give informed consent
* Disorders that preclude the ability to judge pain or discomfort associated with intravitreal injection
* Disorders that preclude the ability to assess for complications of intravitreal injection
* Inability to assess the landmarks by which localization of intravitreal injection sites is determined, such as obscured corneal limbus
* Inability to communicate directly to the physician and immediately after the procedure the level of pain or discomfort
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical College of Wisconsin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dennis Han
Professor of Ophthalmology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dennis P Han, MD
Role: PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Froedtert and Medical College of Wisconsin Eye Institute
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO00021075
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.